ATE391513T1 - Verfahren zur identifizierung von regulatorischen tr1-lymphozyten durch anwesenheit und überexpression von spezifischen molekülen und seine anwendung - Google Patents
Verfahren zur identifizierung von regulatorischen tr1-lymphozyten durch anwesenheit und überexpression von spezifischen molekülen und seine anwendungInfo
- Publication number
- ATE391513T1 ATE391513T1 AT04767439T AT04767439T ATE391513T1 AT E391513 T1 ATE391513 T1 AT E391513T1 AT 04767439 T AT04767439 T AT 04767439T AT 04767439 T AT04767439 T AT 04767439T AT E391513 T1 ATE391513 T1 AT E391513T1
- Authority
- AT
- Austria
- Prior art keywords
- overexpression
- identifying
- application
- molecules
- specific molecules
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 210000004698 lymphocyte Anatomy 0.000 title abstract 3
- 230000002018 overexpression Effects 0.000 title abstract 2
- 230000001105 regulatory effect Effects 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 abstract 2
- 230000001363 autoimmune Effects 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 abstract 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 abstract 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 abstract 1
- 102100025305 Integrin alpha-2 Human genes 0.000 abstract 1
- 102100025390 Integrin beta-2 Human genes 0.000 abstract 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 abstract 1
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 abstract 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 abstract 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000011002 quantification Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0307601A FR2856700B1 (fr) | 2003-06-24 | 2003-06-24 | Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE391513T1 true ATE391513T1 (de) | 2008-04-15 |
Family
ID=33515351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04767439T ATE391513T1 (de) | 2003-06-24 | 2004-06-24 | Verfahren zur identifizierung von regulatorischen tr1-lymphozyten durch anwesenheit und überexpression von spezifischen molekülen und seine anwendung |
Country Status (11)
Country | Link |
---|---|
US (1) | US7771932B1 (de) |
EP (1) | EP1660118B1 (de) |
JP (1) | JP4546955B2 (de) |
AT (1) | ATE391513T1 (de) |
AU (1) | AU2004251462B8 (de) |
CA (1) | CA2529941C (de) |
DE (1) | DE602004013018T2 (de) |
DK (1) | DK1660118T3 (de) |
ES (1) | ES2305836T3 (de) |
FR (1) | FR2856700B1 (de) |
WO (1) | WO2005000344A2 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2575689C (en) * | 2004-08-11 | 2013-04-02 | Txcell | Tr1 cells for use in atherosclerosis |
EP1712615A1 (de) | 2005-04-15 | 2006-10-18 | Txcell | In vitro Herstellung einer Zellpopulation mittels Nährzellen |
PT1739166E (pt) | 2005-07-01 | 2011-09-22 | Inst Nat Sante Rech Med | Obtenção de células tr1 específicas para um auto-antigénio ou antigénio de alimentos a partir de uma população de pbmc ou de leucócito |
WO2007131575A1 (en) | 2006-05-12 | 2007-11-22 | Fondazione Centro San Raffaele Del Monte Tabor | Tolerogenic dendritic cells, method for their production and uses thereof |
EP2050814A1 (de) | 2007-10-17 | 2009-04-22 | Txcell | Zusammensetzungen zur Behandlung von Multipler Sklerose |
KR20100076031A (ko) | 2007-10-17 | 2010-07-05 | 티엑셀 | Tr1 세포, 중간엽 줄기 세포 및 이들의 용도 |
EP2062970A1 (de) * | 2007-11-26 | 2009-05-27 | Txcell | Zusammensetzungen zur Behandlung einer Darmentzündung |
EP2113560A1 (de) | 2008-04-28 | 2009-11-04 | TXCell | Zusammensetzungen zur Behandlung eines Arthritisleidens |
PT2113254E (pt) | 2008-04-28 | 2012-11-26 | Txcell | Composições para o tratamento de um estado inflamatório auto-imune |
EP2221364A1 (de) | 2009-02-23 | 2010-08-25 | TXCell | Zusammensetzungen zur Behandlung eines allergischen oder asthmatischen Leidens |
AU2011364392B2 (en) | 2011-03-25 | 2017-03-02 | Txcell | Method for using regulatory T cells in therapy |
CN104245923B (zh) | 2012-03-02 | 2018-04-20 | 加州大学评议会 | 同种异型抗原‑反应性调节t细胞的增殖 |
CA2877286C (en) | 2012-06-18 | 2023-05-16 | Yale University | Compositions and methods for diminishing an immune response |
US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
JP7287665B2 (ja) * | 2019-06-24 | 2023-06-06 | 国立研究開発法人農業・食品産業技術総合研究機構 | 試験物質の、加齢に伴う粘膜免疫機能の低下を抑制する機能の評価方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277635B1 (en) * | 1992-03-04 | 2001-08-21 | Schering Corporation | Use of interleukin-10 to produce a population of suppressor cells |
FR2824567B1 (fr) * | 2001-05-11 | 2003-08-08 | Inst Nat Sante Rech Med | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene |
AU2004288646A1 (en) | 2003-11-12 | 2005-05-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of lipopeptides for activating T lymphocytes through the skin |
CA2575689C (en) | 2004-08-11 | 2013-04-02 | Txcell | Tr1 cells for use in atherosclerosis |
-
2003
- 2003-06-24 FR FR0307601A patent/FR2856700B1/fr not_active Expired - Fee Related
-
2004
- 2004-06-24 WO PCT/FR2004/001583 patent/WO2005000344A2/fr active IP Right Grant
- 2004-06-24 DE DE602004013018T patent/DE602004013018T2/de not_active Expired - Lifetime
- 2004-06-24 DK DK04767439T patent/DK1660118T3/da active
- 2004-06-24 AT AT04767439T patent/ATE391513T1/de active
- 2004-06-24 ES ES04767439T patent/ES2305836T3/es not_active Expired - Lifetime
- 2004-06-24 AU AU2004251462A patent/AU2004251462B8/en not_active Ceased
- 2004-06-24 CA CA2529941A patent/CA2529941C/fr not_active Expired - Fee Related
- 2004-06-24 EP EP04767439A patent/EP1660118B1/de not_active Expired - Lifetime
- 2004-06-24 US US10/561,517 patent/US7771932B1/en not_active Expired - Fee Related
- 2004-06-24 JP JP2006516319A patent/JP4546955B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2004251462B2 (en) | 2011-05-19 |
AU2004251462B8 (en) | 2011-06-02 |
JP2007520197A (ja) | 2007-07-26 |
DK1660118T3 (da) | 2008-08-11 |
DE602004013018T2 (de) | 2009-07-16 |
EP1660118A2 (de) | 2006-05-31 |
WO2005000344A3 (fr) | 2005-06-09 |
EP1660118B1 (de) | 2008-04-09 |
US7771932B1 (en) | 2010-08-10 |
ES2305836T3 (es) | 2008-11-01 |
DE602004013018D1 (de) | 2008-05-21 |
FR2856700A1 (fr) | 2004-12-31 |
FR2856700B1 (fr) | 2007-06-08 |
WO2005000344A2 (fr) | 2005-01-06 |
CA2529941C (fr) | 2013-08-13 |
AU2004251462A1 (en) | 2005-01-06 |
JP4546955B2 (ja) | 2010-09-22 |
CA2529941A1 (fr) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE391513T1 (de) | Verfahren zur identifizierung von regulatorischen tr1-lymphozyten durch anwesenheit und überexpression von spezifischen molekülen und seine anwendung | |
Lippmann et al. | Commentary on human pluripotent stem cell-based blood–brain barrier models | |
HUP0202532A2 (hu) | Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása | |
WO2004033631A8 (en) | Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using | |
ATE408706T1 (de) | Verfahren zur detektion und zählung von mikroorganismen in einer probe | |
ATE230032T1 (de) | Verfahren zur herstellung von festen trägern für hybridisierung und zur verminderung von nichtspezifischem hintergrund | |
ATE307902T1 (de) | Methoden und testsätze zur probennahme und aufbewahrung von biologischen proben | |
DE69117949D1 (de) | Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis | |
AU5419399A (en) | Method for determining the immune defences of blood, test kit therefor and use of a suitable system for taking blood samples | |
Tinta et al. | Microbial processing of jellyfish detritus in the ocean | |
DE69626418D1 (de) | Verfahren zur bulk-anreicherung von einer zellpopulation oder zellsubpopulation | |
CN109906381B (zh) | 鉴别、靶向以及分离人树突细胞(dc)前体“前dc”的方法及其用途 | |
DE69833660D1 (de) | Nukleinsäuresonden zur detektion von candida-spezies | |
Lorenzo et al. | Contrasting complexing capacity of dissolved organic matter produced during the onset, development and decay of a simulated bloom of the marine diatom Skeletonema costatum | |
ATE389718T1 (de) | Isolierung von nukleinsäuren unter verwendung eines polykationischen polymers als fällungsmittel | |
Czarkwiani et al. | Neurogenesis during brittle star arm regeneration is characterised by a conserved set of key developmental genes | |
ATE440968T1 (de) | Verfahren zur diagnostizierung von aspirinunverträglichkeit | |
Weisgrau et al. | Neutrophil progenitor populations of rhesus macaques | |
Maurer et al. | Protein expression differs between neural progenitor cells from the adult rat brain subventricular zone and olfactory bulb | |
RS52875B (en) | QUICK DIAGNOSTIC TEST FOR ALCHAIMER DISEASE | |
ATE534907T1 (de) | Verfahren für den nachweis von l523s-expression in biologischen proben | |
DE60322240D1 (de) | Katzenpankreas-lipase-zusammensetzung und verfahren zur herstellung und verwendung einer solchen zusammensetzung | |
FR2886735B1 (fr) | Procede de marquage ou de traitement d'un echantillon biologique contenant des molecules biologiques d'interet, notamment des acides nucleiques | |
ATE523599T1 (de) | Verfahren zum nachweis von prp unter verwendung eines wenigstens eine positive ladung und/oder wenigstens eine osidische bindung enthaltenden moleküls und eines von einem proteinliganden verschiedenen liganden | |
ATE514779T1 (de) | Rheumatische arthritis-gen und verfahren für die diagnose von rheumatischer arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1660118 Country of ref document: EP |